MedTrace Logo

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

NCT01172652 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-04-08

Study results available
· View outcomes & findings →

Summary

The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.

Conditions

Interventions

DRUG

Ziprasidone

The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.

DRUG

Placebo

Inactive control

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of South Florida

    collaborator OTHER

  • Lindner Center of HOPE

    collaborator OTHER

  • VA Palo Alto Health Care System

    lead FED

Principal Investigators

  • Trisha Suppes, MD, PhD · VA Palo Alto Health Care System & Stanford School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01172652 on ClinicalTrials.gov